Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

[1]  M. Genovese,et al.  Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years , 2021, Annals of the Rheumatic Diseases.

[2]  R. Westhovens,et al.  Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3 , 2021, RMD Open.

[3]  Leong Khai Pang,et al.  Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region , 2021, The Lancet regional health. Western Pacific.

[4]  I. McInnes,et al.  Filgotinib, a Novel JAK1-Preferential Inhibitor for the Treatment of Rheumatoid Arthritis: An Overview from Clinical Trials. , 2021, Modern rheumatology.

[5]  D. M. van der Heijde,et al.  Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial , 2021, Annals of the Rheumatic Diseases.

[6]  J. Hazes,et al.  The number of risk factors for persistent disease determines the clinical course of early arthritis , 2021, Rheumatology.

[7]  D. M. van der Heijde,et al.  Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial , 2021, Annals of the Rheumatic Diseases.

[8]  D. Veale,et al.  Long-term remission and biologic persistence rates: 12-year real-world data , 2021, Arthritis Research & Therapy.

[9]  J. Boedecker,et al.  Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network , 2020, medRxiv.

[10]  A. Cope,et al.  A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis , 2020, Arthritis Research & Therapy.

[11]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[12]  Fredrik D. Johansson,et al.  Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development , 2020, ACR open rheumatology.

[13]  E. Keystone,et al.  Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials , 2019, Rheumatology.

[14]  P. Kiely,et al.  Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review , 2019, Rheumatology advances in practice.

[15]  By Michael Marron-stearns.  2019 Update : What to , 2019 .

[16]  P. Durez,et al.  Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. , 2018, Clinical and experimental rheumatology.

[17]  G. Littlejohn,et al.  Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study , 2017, International journal of rheumatic diseases.

[18]  D. M. van der Heijde,et al.  Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials , 2016, Arthritis Research & Therapy.

[19]  R. Westhovens,et al.  The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. , 2014, Seminars in arthritis and rheumatism.

[20]  B. Dijkmans,et al.  A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study , 2010, Annals of the rheumatic diseases.

[21]  D. Heinegård,et al.  Prognostic laboratory markers of joint damage in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.